There is also evidence that a decrease in testosterone may contribute to the development of HT and that ADT may increase the prevalence of HT in PC patients, especially among those using gonadotropin-releasing hormone (GnRH) receptor agonists25,26. Here, GNRHR is linked to hematocrit.